1 Followers
26 Following
satish

satish

HbA1c Testing Devices Market To Mirror A Worldwide Expansion Throughout 2018 – 2026

HbA1c test is used to screen and diagnose for diabetes and prediabetes in patients. Hemoglobin molecule from the blood cell sticks to the glucose that gives rise to glycosylated hemoglobin molecule termed as hemoglobin A1C (HbA1C). Patients with high glucose level have more HbA1C present in blood. Average blood glucose level of a person can be diagnosed by measuring this glycosylated hemoglobin molecule. It is important for diabetic patient to know the glucose level, as there might be risk of diabetes related complications. HbA1c test is considered more effective than checking the blood glucose level. Blood glucose level gives the presence of glucose at a single point time whereas, the HbA1c test gives blood glucose level status for 2-3 months.

 

Increase in healthcare expenditure over diabetes management is owing to the growth of HbA1c testing devices market

Growing diabetes patient population globally is one of the important factor driving the growth HbA1c testing devices market. According to World Health Organization (WHO), the number of patients with diabetes has increased from 108 million in 1980 to 422 million in 2014. Around 5 million deaths were reported in 2015 due to diabetes and 2.2 million deaths were attributed to high blood glucose level. The data given by International Diabetes Federation showed the expenditure of 673 billion USD on diabetes in 2015. Additionally, rise prescription by physicians for HbA1c test is contributing to the growth of HbA1c testing devices market.

 

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/945

 

Wide use of bench top devices in diagnostic laboratories owing to domination of device segment

The global HbA1c testing devices market is segmented by device- type, by technology, by end users, and by region

On the basis of device- type, the HbA1c testing devices market is segmented into

  • Bench top device

  • Handled device

 

Rising diabetic population is attributed to the growth of HbA1c testing devices market in Asia Pacific

Regional segmentation of HbA1c testing devices market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The increase in number of patient population in North America is fuelling the growth of HbA1c testing devices market. Furthermore, the factors like established healthcare infrastructure and adoption to the technologically advanced medical devices, are helping North America to dominate in the HbA1c testing devices market. According to recent data given by International Diabetes Federation, there are around 109 million people in China and 69 million people in India with diabetes. The large number of diabetic population, unmet health needs, and development in healthcare sector are fuelling the growth of HbA1c testing devices market in Asia Pacific.

 

Product development is helping the organizations in HbA1c testing devices market to hold the top position

Key industry players operating the global HbA1c market includes Abbott Laboratories, Transasia Biomedicals limited, Alere Incorporated, Arkray Incorporated, Danaher Co., Bio-Rad Laboratories, Siemens Healthcare, F.Hoffmann-La Roche Limited, and Trinity Biotech Plc. The industry players are likely to get involved in product development for higher accuracy, reliable results, and quicker turnaround time for the analyzers. The factors like product development and approval of devices for diagnosis of diabetes are helping the organizations to hold the maximum share in the HbA1c testing devices market.

 

Click to read more on HbA1c Testing Devices Market
 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 

Muscular Dystrophy Treatment Market Demand, Key Drivers, Players and Trend Analysis

Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles.

Holter Monitor Market Forecast To 2026 Based On Market Data Of The Period 2018-2026

Holter monitor is a battery-operated portable device that measures and records cardiac activity for 24 to 48 hours. Holter monitors device are used to detect and analyze cardiac arrhythmia, atrial fibrillation, and bradycardia. The device has silver dollar-sized electrodes, which can be attached to patients. The device is powered by small battery electrocardiogram (ECG) appliance. The system is incorporated with recorder and software to record heart rhythm and analyze the recorded data respectively. It is majorly used in patients diagnosed with coronary artery disease or post infarction period. According to the American Heart Association, around 17.3 million deaths are caused due to cardiovascular disease worldwide annually and number is anticipated to reach around 23.6 million by 2030. Increasing prevalence of cardiovascular disorders, adoption of preventive healthcare measures by population are key drivers for growth of global holter monitoring market.

 

Request Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/937

 

Holter Monitor Market Taxonomy

On the basis of Product Type, Holter Monitor Market is segmented into:

  • Single channel

  • Double channel

  • Multi-channel

On the basis of End user, Holter Monitor Market is segmented into:

  • Hospitals

  • Ambulatory surgical center

  • Clinic

  • Homecare

Increasing prevalence of cardiovascular diseases around the globe is expected to fuel growth of the holter monitor market over the forecast period

On the basis of Geography, Holter Monitor Market is segmented into North America, Latin America, Asia Pacific, Middle East and Europe. Increasing geriatric population and adoption of advanced healthcare facilities by patients are major factors expected to drive the growth of global cardiac holter monitor market over the forecast period. Geriatric population is more prone to heart diseases as heart muscles loose the resistance and capability to respond to different pressure rates, in turn making them more susceptible to cardiac disorders. According to the Center for Disease Control and Prevention (CDC), in 2012, around 117 million adults were suffering from one or more chronic conditions. North America holds dominant position in holter monitor market, owing high adoption of minimally aggressive diagnostic tools by patients and supportive government regulations and funding for treatment of cardiovascular disorder. According to the report published by American Heart Association in 2015, an estimated 450,000 deaths due to cardiac disorders in the U.S.

 

The holter monitor device market of Asia Pacific region is expected to grow at significant rate over the forecast period, owing to increasing prevalence of chronic disorder cases and unhealthy nutrition habits among rural population. Increasing awareness regarding treatment of cardiac arrhythmia and atrial fibrillation along with various programs conducted by world health organization (WHO) for prevention of cardiovascular disorders are major factors fueling growth of the holter monitor market in Asia Pacific.

Integration of advanced technologies in medical devices is expected to boost growth of the market. For instance, in 2015, Philips healthcare incorporated wireless and Bluetooth technology in cardiac hotler monitoring device. Shifting manufactures method towards customer centric development of products is expected to propel growth of the global holter monitor market over the forecast period.

 

Key players operating holter equipment market include GE Healthcare, FUKUDA DENSHI, Koninklijke Philips N.V., Philips Healthcare, Nasiff Associates, Inc., LifeWatch AG, Schiller AG, Fukuda Denishi Co. Ltd. Spacelabs Healthcare, and Welch Allyn.

Click to read more on Holter Monitor Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Holter Monitor Med device makers look ahead to growth despite regulatory challenges

 

Increasing prevalence of cardiovascular diseases around the globe is expected to fuel growth of the holter monitor market over the forecast period.

 

Myeloproliferative Neoplasms Treatment Market Analysis, Consumer Distribution, Companies List,

Myeloproliferative Neoplasms Treatment Market Accelerates Business to Gain High Revenue during 2018-2026

Myeloproliferative Neoplasms (MPNs) are a group of rare disease, in which the bone marrow produces excess blood cells. It can be white blood cells, red blood cells or platelets. The overproduction of blood cells by the bone marrow creates hindrance in the smooth flow of blood, which leads to various symptoms such as progressive cytopenias, cachexia and weight loss, splenomegaly, and blastic transformation. These conditions are developed gradually over a period of time. Most people are diagnosed after the age of 60 years, when they were accompanied by many other health issues, makes the treatment more difficult.

 

The major symptoms associated with MPNs include bleeding problem, anemia, chest pain, fatigue, enlarged spleen, and weight loss. According to Annals of Hematology, approximately 90% of patients has experienced MPN-symptoms in past 12 months, wherein women are reported to have higher overall burden than men. The treatment for myeloproliferative neoplasms is mainly aimed to reduce the excess number of blood cells circulation. The concept of myleoproliferative disease was first given by hematologist Williom Dameshek in 1950. However, in 2008, World Health Organization (WHO) classified hematologic malignancies and renamed myloproliferative diseases to myeloproliferative neoplasms.

 

Request For a Sample Copy of This Research Report:https://www.coherentmarketinsights.com/insight/request-sample/930

 

Rising awareness of molecular abnormalities and cellular pathways involved in the pathogenesis of MPNs is expected to facilitate the development of novel drugs, propels the Myeloproliferative Neoplasms treatment market growth in the near future

Myeloproliferative neoplasm can significantly affect the quality of life of the patient. The complication and treatments as well as the physiological strains of cancer diagnosis can affect the physical and emotional wellbeing of patients. Effects of complication vary from depression, fatigue, pain or depression with suicidal ideation. Moreover, patients can experience few or no symptoms for a longer period of time. MPNs can be cured with proper monitoring and treatment. There has been a major revolution in the management of MPNs by introduction of JAK1 and JAK2 inhibitor and ruxolitinib. Ruxolitinib inhibits these two enzymes in order to manage MPNs. The drug has also been proven as an alternative therapy for the treatment of polycythemia vera. Further, the therapeutic armamentarium for MPN is still inadequate for normalization of life span, reduction in cardiovascular complications, and prevention of hematological progression.

 

Rising awareness of molecular abnormalities and cellular pathways involve in the pathogenesis of MPNs is expected to facilitate the development of clinical trials with novel drugs, either alone or in combination with ruxolitinib. Interferon (IFN) is a drug that has proven as an effective alternative for MPNs patients. Better understanding of its mechanism of action for MPNs could lead to better interferon compound and potential drugs. In 2017, MPN research foundation have initiated a MPNRF Interferon (IFN) multi-center project which is expected to bring together internationally recognized experts to determine cytokine-driven pathways that affect the path of the MPNs. It is a closely-related group of progressive blood cancer which is also among the lucrative opportunities for major players in the Myeloproliferative Neoplasms treatment market.

 

Collaboration among the biotech and pharmaceutical companies to identify new drugs for MPNs is expected to accelerate the market growth

Novartis AG and Incyte Corporation are among the key players in Myeloproliferative Neoplasms treatment market. According to MPN research foundation, biotech and pharmaceutical companies are expected to propel the demand for improved treatments and quickly connecting patients with latest treatment options. It is expected to lead developing relationships with biotech and pharmaceuticals companies to identify new areas for scientific exploration. For instance, Incyte Corporationis is developing inhibitor for Janus Kinase (JAK) and also focusing on the discovery, development, and commercialization of proprietary therapeutics globally.

 

Click To Read More On Myeloproliferative Neoplasms Treatment Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Muscular Dystrophy Treatment Market: Growth, Development, Trends, Demand, Share, Analysis and Forecast 2026

Muscular Dystrophy is characterized by a collection of muscle-wasting conditions. The disorder is caused by genetic mutations which interfere with the production of muscle protein dystrophin, necessary to build muscles. Muscular dystrophy is a genetic disease, consequently, the chance of an individual developing a disease increases with a history of muscular dystrophy in the family. The symptoms include shortening of muscles and tendons, the curvature of spine, weakening of heart muscles leading to cardiac problems, and breathing problems. The most common forms of muscular dystrophies include duchenne muscular dystrophy, becker muscular dystrophy, myotonic disease, congenital disease and oculopharyngeal muscular dystrophy. The cure for any form of muscular dystrophy is currently unspecified, but the symptoms can be relived through physical therapy, exercise, rehabilitative devices like a powered wheelchair, respiratory care and surgery.

 

Request For Sample Copy of This Business Report: https://www.coherentmarketinsights.com/insight/request-sample/914

 

The common muscular dystrophy types:

  1. Duchenne muscular dystrophy (DMD)

Most common form of muscular dystrophy in children caused by lack of protein dystrophin. The onset of symptoms is seen at the age of 3, generally wheelchair-bound by 12. The Curvature in spine, heart, and lungs effects are the symptoms. Duchenne muscular dystrophy (DMD) is an X-linked disease predominantly affecting males, resulting in uniform muscle wasting. Death occurs due to respiratory failure by mid-twenties.

  1. Becker muscular dystrophy(BMD)

Similar to Duchenne, however, with later onset and slow progression of the illness. Death occurs in the mid-forties.

 

Molecular therapy segment is expected to generate larger revenue with higher efficiency in clinical trials

The global muscular dystrophy treatment market is segmented on the basis of treatment, diagnosis, end user and geography.

Specific guidance by FDA is expected to dominate North America the global market

Regional segmentation of the global muscular dystrophy treatment market by Coherent Market Insights comprises North America, Latin America, Europe, Asia-Pacific and The Middle East and Africa. According to the Centers for Disease Control and Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to 24 years were reported to have duchenne muscular dystrophy or becker muscular dystrophy in the United States. North America is expected to dominate the global muscular dystrophy treatment market owing to the absence of marketed pharmacological therapies indicated to treat muscular dystrophy, rising prevalence of the disease and rising research and development for producing effective drugs. Europe is expected to boost the market share in the forecast period with the growing public awareness and increasing research activities.

Launch of efficient corticosteroids to rise the market demand

The key players operating the global muscular dystrophy treatment market include Santhera Pharmaceuticals, PTC Therapeutics, BioMarin Pharmaceutical, Sarepta Therapeutics and Eli Lilly. The approval and launch of oral corticosteroid Emflaza in 2017, has been found highly effective in patients to regain strength and restore their ability to walk. The other vendors include Acceleron Pharma, Capricor Therapeutics, Bristol-Myers Squibb, Lexicon Pharmaceuticals, and Pfizer.

 

Download The PDF Brochure of This Business Report: https://www.coherentmarketinsights.com/insight/request-pdf/914

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Batten Disease Treatment Market: Key Industry Trends, Growth Rate & With Forecast To 2026

Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms. Batten disease is one of the approximately 50 diseases that fall under the category of lysosome shortage disorders. The batten disease also referred as Neuronal ceroid Lipofuscinoses (NCLs), which is a class of life-limiting genetic neurogenerative diseases that are caused due to abnormality of genes resulting in their inability to synthesize required protein. This disease is characterized by malfunctioning of body, which usually appears around the age of 2-10 with symptoms, such as seizures or gradual onset of vision problem. The early signs may show subtle changes in behavior and learning, however over time, the child suffers from mental impairment, progressive loss of sight, speech and motor reactions, worsening seizures, eventually leading to blindness dementia, and finally death. These disease is diagnosed with the help of certain tests, such as blood or urine tests, skin or tissue dampening, brain scans, and imaging techniques, which includes, computed tomography (CT) or magnetic resonance imaging (MRI). The batten disease is characterized into four types as follows:

  • Infantile NCL: more than 2 years

  • Late Infantile NCL: 2-4 years (Life span of child varies between 8-12 years)

  • Juvenile NCL: 5-8 years (Life span varies between teens to early 20s)

  • Adult NCL: more than 40 years (Variable lifespan)

Request Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/831

 

European countries facing rising prevalence and incidence of batten disease

According to the Centers for Disease Control and Prevention (CDC), Batten disease is observed in 2-4 per 100,000 live births in the United States on an average. The Batten disease although is rare but has high incidence rates in Finland, Sweden, and other parts of the Europe as compared to rest of the world. According to the Batten Disease Support and Research Association, the batten disease has often been encountered in more than one children of the same family. The Daily News and Analysis article published in June 2016 suggests that, over 20 million children in India suffer from rare diseases, having expensive treatments. This creates opportunities for the sustaining as well as upcoming market players by understanding the potential held by the global batten disease treatment market.

The global batten disease treatment market is segmented on the basis of therapy and geographical regions.

On the basis of therapy, the global batten disease treatment market is segmented as

  • Occupational Therapies

  • Physical Therapies

Attempts by collaborations of research bodies for introduction to reliable treatment options for batten disease giving hopes to commoners

The batten disease treatment market is not dense on the global level, however the developed economies of North America and Europe are expected to contribute to the growth of the market. This attributes to the increasing incidence of batten disease and high prevalence rates in American as well as European countries. For instance, a joint study between Baylor College of Medicine, Texas Children’s Hospital, and King’s College London have discovered a treatment that has helped to improve the neurological symptoms in the mouse model of juvenile batten disease. This research held a novel approach of counteracting the accumulation of the cellular waste in Batten disease by acting on TFEB, which is a master transcription factor that stimulates the production of lysosomes by the cell body and directs cellular apoptosis. This has brought a ray of hope to patients and families affected by battens disease.

 

Improper treatment facility for batten disease responsible to attract the attention of various players to enter the untapped potential batten disease treatment market

The rising incidence of the batten disease without effective treatment option for the prevention and cure of the disease is the primary driver for batten disease market, due to which several companies are vying to enter into the untapped global batten disease treatment market. However, the lack of awareness among manufacturers and patient population as well as unavailability of treatment for this disease are greatly hampering the growth of the global batten disease treatment market.

Although, the global batten disease treatment market is very scarce, few key players offering cell regeneration therapies and few other forms of medication include Seneb BioSciences, Inc., BioMarin Pharmaceuticals and ReGenX Biosciences LLC. The U.S. FDA has recently approved BioMarin’s first ever drug to treat batten disease known as Brineura in 2017.

 

Click to read more on Batten Disease Treatment Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Batten Disease Treatment Market Overview and Share Forecasted to 2026

Batten disease is a rare, inherent, and fatal autosomal recessive neural disorder that begins in the childhood but may take a few years to show symptoms. Batten disease is one of the approximately 50 diseases that fall under the category of lysosome shortage disorders.

Multiple Myeloma Drugs Market Estimated To Reach Significant Size 2018-2026

Multiple Myeloma Drugs Market Present Chances, Trends, Value Chain And Stakeholder Analysis 2018-2026

Multiple Myeloma is a form of cancer formed by malignant plasma cells. Malignant tumors are formed from highly unstable abnormal cells travelling via the blood stream, circulatory system, and lymphatic system. The plasma cells become cancerous and vigorously proliferative, producing tumor called plasmacytoma that prevents the bone marrow from producing healthy blood cells and immunoglobulins. The formation and proliferation of myeloma cells result in fewer leukocyte, erythrocyte, and platelet cell formation causing a damaged immune system. Gastrointestinal problems, enlarged organs, kidney damage, rapid weight loss, bone pain, and fever are some of the common symptoms of multiple myeloma. Multiple myeloma is considered to be the third most common blood cancer followed by lymphoma and leukemia.

 

Request Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/839

 

Introduction of monoclonal antibodies with safety profile to fight myeloma cells is expected to drive themultiple myeloma drugs market

The increasing microRNA therapeutics, nanomedicine platform emergence, and constant introduction of effective and safe therapeutics drives the growth of multiple myeloma drugs market. The drugs market is expected to gain momentum with the addition of monoclonal antibodies and Histone Deacetylase (HDAC) inhibitors to the current therapeutics array. The biologic therapy of monoclonal antibodies including DARZALEX and EMPLICITI are largely preferred by the physicians owing to the established clinical profile. The growing prevalence of the disorder with the surging elderly population, the inefficiency of the current medication augments to invest in research and development, thereby driving the global market in the forecast period. Additionally, the supportive treatment demand for restoration procedures including point of care technologies, approved safety profile and efficiency of monoclonal antibodies is expected to broaden the drug treatment received by the patients.

 

Novel targeted therapy segment is expected to fuel the multiple myeloma drugs market

The global multiple myeloma drugs market is segmented on the basis of technology, diagnosis, surgery, end user and geography.

On the basis of drug type, the global multiple myeloma drugs market is segmented into:

  • Immunomodulating agents

  • Proteasome inhibitors

  • Histone Deacetylase (HDAC) inhibitors

  • Steroids (Corticosteroids)

  • Monoclonal antibodies

On the basis of distribution channel, the global multiple myeloma drugs market is segmented into:

  • Hospital Pharmacy

  • Retail Pharmacy

  • ePharmacies

 

Presence of major key players accounts for the drastic dominance of Europe in the global multiple myeloma drugs market

Regional segmentation of the global mouth ulcers treatment market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, The Middle East and Africa. According to the American Cancer Society’s estimates for 2017, about 30,280 new cases will be diagnosed including 17,490 in men and 12,790 in women in the U.S., with an expected 12,590 deaths, thus indicating rising prevalence of multiple myeloma cases in North America with the rise in effective treatment. Also, North America is expected to dominate the multiple myeloma drugs market owing to change in lifestyle habits, obesity, and the launch of various multiple myeloma therapies. For instance, the launch of NINLARO, DARZALEX, and FARYDAK will considerably drive the growth of the market in the forecast period. The European market is expected to rise drastically owing to the presence of major players, favorable reimbursement policies. and immediate FDA drug approval rates.

 

Launching drugs due to high unmet medical needs of patients is a strategy adopted by key players

Key players operating the global multiple myeloma drugs market include NovartisJohnson & JohnsonElgene, Takeda Pharmaceuticals, and Amgen. The strategies adopted by the key players include advances in research activities, the launch of novel therapies specific for effective treatment due to unmet medical needs increase the competition among vendors. Other leading vendors include Acceleron Pharma, Bristol-Meyer Squibb, Sanofi, GlaxoSmithKline, and Merck.

 

Click to read more on Multiple Myeloma Drugs Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Nursing Care Services Market Scope, Industry Overview And Growth Rate, Research Report 2018-2026

Nursing care services provide special care to patients suffering from chronic diseases such as Parkinson’s disease, Alzheimer’s disease, patients who need care for injury, and who are ill and require continuous attendance.

Nursing Care Services Market Size, Demand, Type & Applications, Market Status And Forecasts To 2026

Nursing care services provide special care to patients suffering from chronic diseases such as Parkinson’s disease, Alzheimer’s disease, patients who need care for injury, and who are ill and require continuous attendance. At the nursing care services center, trained professionals provide care facilities such as dressing, personal hygiene, and timely medications. This industry provides patient nursing, rehabilitation services, and living accommodations to people with some disability or chronic disorders. These service centers also help the speech therapists and physical therapist by assisting them and monitoring interventional medications.

 

Rising geriatric population to fuel the growth of nursing care services market

Increase in number of patients with chronic diseases such as Alzheimer’s disease and dementia is the major driving factor for the growth of nursing care services market. According to World Health organization (WHO), there are around 47.5 million patients suffering from dementia globally every year. Moreover, the increasing geriatric population is also stimulating the growth of nursing care services market. The data given by Centers for Disease Control and Prevention (CDC) informs that in 2014, there were around 15,600 number of nursing homes in the U.S. in that the proportion for nursing care services for-profit ownership was 69.8%.

 

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/800

 

For-Profit nursing care services segment holds the major share in the nursing care services market due to increase in awareness about skilled nursing care

The global nursing Care Services market is segmented by patients group, type of connectivity, and industry product.

On the basis of patients group, the nursing Care Services market is segmented into

  • People with chronic diseases

  • Aged people

  • Injured people

  • Disabled people

  • Retirement homes

  • Rest homes

 

Growing patient population of Alzheimer’s disease contributing to the progress of nursing care services market in North America

Regional segmentation of nursing Care Service market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, the Middle East and Africa. North America holds the major share in the nursing care services market due to the increased awareness about importance of nursing care services in this region, well defined regulatory framework of this region, and provision of reimbursement coverage. Additionally, growing cases of chronic diseases which requires special care facilities is driving the growth of nursing care services in this region. For instance, the data provided by Alzheimer’s Association in Alzheimer’s disease Facts 2017  the number of people with Alzheimer’s are estimated 5.3 million of 65 age and older and 200, 000 young individual with Alzheimer’s disease in U.S.

 

Key business players are trying to provide quality service with the help of Internet of Things

Key industry players operating in the nursing care services market include Golden Living, Apria Healthcare Group Incorporated, Linacre Inc., Genesis healthcare, Sun Healthcare Group Incorporated, Sunrise Senior Living Incorporated, Genitive, Emeritus Co., and Brookdale Senior Living & Expenditure Incorporated. Market players have increased their spending in residential nursing care services and home healthcare services market. The industry players are approaching more patients with the help of Internet of Things (IoT). Through, IoT the centers can provide high quality service to patients and keep track on health of aged and chronically ill patients.

 

Click to read more on Nursing Care Services Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Solid Tumors Treatment Market Analysis, Segmentation, Key Players, Opportunities And Forecast 2018-2026

Solid Tumors Treatment Market Size Historical Growth Analysis To 2026

A solid tumor is an abnormal mass or lump of tissues without liquid or cysts. It is not necessary that tumor should always be cancerous. On the basis tumor nature, it can be classified as the malignant tumor (cancerous) and the benign tumor (non-cancerous). Based on the cell type, tumors can be classified as carcinomas, sarcomas, and lymphomas. The Solid tumors might occur in several places such as muscle, bone, and organs. Treatments for solid tumors include prevention of tumor and combination of surgery, chemotherapy, and radiation therapy. However, new forms of treatment are emerging in the market.

 

Emerging trend of Biosimilars therapy is expected to propel the growth of solid tumors treatment market

According to data published in International Journal of Pharma Sciences and Research (IJPSR) in 2011, there were around 9 million deaths due to cancer. In 2015, 11.4 million people are expected to die in 2030, among this prevalence of cancer maximum is due to solid tumors. Growing prevalence of solid tumors is the major driving factor for the growth of solid tumors treatment market. Additionally, some other factors fuelling the growth of solid tumors treatment market include unmet demand for cancer treatment and rising investment in the research and development of cancer drugs. However, increase in the volume of generic therapeutic products, the high cost of cancer therapy, and growing drug patent cliff are some of the restraints that might hinder the growth of solid tumors treatment market. Moreover, the emerging trend of biosimilars is contributing to the growth of solid tumors treatment market due to their low cost and their similarity to originator compound. For instance, some of the biologics available for solid tumors treatment includes Herceptin, MabThera, Avastin, and Erbitux. The advantages of this biosimilars to overcome the limitations of generic drugs in the treatments is expected to propel the growth of solid tumors treatments market.

 

Request For Sample Copy of This Research Report: https://www.coherentmarketinsights.com/insight/request-sample/793

 

Chemotherapy segment holds the maximum share in solid tumor treatment market due to its efficacy by combining with some other therapies to treat solid tumors.

The global solid tumors treatment market is segmented by therapy, by application, by the end user, and by region.

On the basis of therapy, solid tumors treatment market is segmented into

  • Radiotherapy

  • Chemotherapy

  • Immunotherapy

  • Hormone therapy

  • Targeted therapy

 

Rising incidences of solid tumor cases in North America is the factor contributing to the growth of solid tumor treatment market

Regional segmentation of Solid Tumors Treatment market by Coherent Market Insights comprises of North America, Latin America, Europe, Asia Pacific, Africa, and the Middle East. North America dominates in the solid tumors treatment market due to the presence of well-established healthcare infrastructure, and rise in the number of solid tumor cases.

 

Advanced drug therapy is expected to help the industry players to sustain in the solid tumors treatment market

Key industry players operating solid tumors treatment market include Abbott Laboratories Inc., Biogen Idec Incorporated, AstraZeneca Plc., Johnson & Johnson Company, Amgen Inc., Bristol Myers Squibb Company, GlaxoSmithKline Plc., Sanofi, and Baxter International Incorporated. Advancements in the cancer therapy such as nanomedicines used for the treatment of cancer might help the industry players to provide effective patient care in the solid tumors treatment. Whereas, stringent regulatory policies for drug manufacturing may restrain the growth of the market. For instance, by regulations provided by the Indian government in late 2012, there are cap prices of 348 drugs on Essential Drug List (EDL), and drug manufacturers need to keep the cost of their drugs below the ceiling price.

 

Click to read more on Solid Tumors Treatment Market

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Medical Plastic Extrusion Market Size, Key Manufactures, Cost Structures And Competitors Analysis, 2018-2026